NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
Mayo Clinic
Turning Point Therapeutics, Inc.
Bristol-Myers Squibb
AbbVie
Shenzhen BinDeBio Ltd.